During the BIO International Convention 2026 (June 22–25) in San Diego, BioSpectrum Asia spoke with Lan Nguyen, Ch...
During the BIO International Convention 2026 (June 22–25) in San Diego, BioSpectrum Asia spoke with Ella Woger-Nie...
While most cardiovascular research has traditionally focused on the heart and large blood vessels, a growing body of evi...
As obesity treatment enters a new phase of innovation, the industry is increasingly looking beyond GLP-1 therapies to ad...
As the pharmaceutical industry advances towards increasingly complex, poorly soluble drug candidates, formulation has ...
As obesity treatment evolves beyond weight loss toward comprehensive cardiometabolic disease management, pharmaceutical ...
There's a particular sound a convention floor makes when an industry has decided to stop apologising for itself....
Few therapeutic areas have witnessed the level of progress achieved in HIV over the past three decades...
While antimicrobial resistance (AMR) is often overshadowed by high-profile therapeutic areas such as oncology, its growi...
Artificial intelligence has long promised to transform healthcare, yet widespread adoption has often been hindered by ch...
Alzheimer's disease research has entered a pivotal new phase following the arrival of the first disease-modifying therap...
As cannabis use expands globally and regulatory frameworks continue to evolve, healthcare systems are increasingly confr...
Autoimmune and inflammatory diseases frequently affect the eye, yet ophthalmology has largely remained on the sidelines ...
The search for safer and more effective pain therapies remains one of medicine's most pressing challenges. Despite advan...
The COVID-19 pandemic demonstrated that scientific discovery can move at extraordinary speed, but it also expose...
As artificial intelligence reshapes the future of genomic medicine, WhiteLab Genomics is positioning itself at t...
Artificial intelligence is rapidly transforming biologics discovery, but the industry's focus is shifting from generatin...
Despite decades of advances in oncology, many solid tumours remain difficult to treat effectively without exposing patie...
As advanced therapeutics move from scientific promise to commercial reality, the industry's focus is shifting be...
The RNA revolution is entering a new chapter. While mRNA transformed the industry's perception of nucleic acid therapeut...
Cancer drug discovery is entering a more disciplined era. Investors, partners, and clinicians are increasingly focused o...
Cancer immunotherapy is entering a new phase—one that extends beyond targeting individual tumour cells and towards...
After several years of volatility, biotechnology financing has returned—but under very different rules. Investors ...
As biotechnology enters an increasingly data-driven era, organisations are rethinking how discovery, clinical developmen...
As cell and gene therapies move from clinical promise to commercial reality, the industry is increasingly recognising th...
